Dr. Luis Alberto Diaz Jr., MD

Dr. Diaz practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Diaz's NPI, 1689601460, was assigned on June 27, 2006. Dr. Diaz graduated from University Of Michigan Medical School in 1998. Dr. Diaz holds Maryland license D57984.

Dr. Diaz's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Diaz's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Diaz practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Diaz's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Diaz's licenses on file in 3 states: Maryland, New Jersey and New York.

Dmand AI lists colorectal cancer among the conditions Dr. Diaz treats.

CMS data shows 87 Medicare services from Dr. Diaz across 2 procedure codes in 2024, all of them office visits, for 32 Medicare patients. Medicare paid $8,830 for them. Every service was in an office.

CMS counts 32 Medicare patients who saw Dr. Diaz in 2024. The largest group is 65 to 74, with 17 patients. 75% of them have cancer, and 72% have high cholesterol. Their average risk score is 2.30, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Diaz's median patient age at 68, with 42% women.

In 2024, Dr. Diaz wrote 26 Medicare Part D claims. 65% of them were for generic drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 76 out of 100 for Dr. Diaz for performance year 2024, reported as part of a group. Dr. Diaz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Diaz as offering telehealth.

Dmand AI links 358 papers to Dr. Diaz, published from 2003 to 2024. 2018 was the busiest year, with 11. The most frequent topics are Pemphigus, Autoantibodies and Pemphigoid, Bullous. Dr. Diaz has published most often in J Invest Dermatol. Dr. Diaz's most frequent co-authors are Grant James Anhalt, MD, Donna Aline Culton, MD and Chetan Bettegowda, MD, PhD.

Dmand AI links Dr. Diaz to 4 clinical trials, 2 of them phase 2 studies. Conditions studied include Carcinoma, Pancreatic Ductal, Hypoxia and Pancreatic Neoplasms. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sponsors the most, 3.

CMS Open Payments shows 71 general payments to Dr. Diaz from 7 drug and device companies from 2016 to 2024. Travel and lodging make up the largest share, 52% of the total. Merck Sharp & Dohme Corporation paid the most, $46,723. It also lists 1 research payment totaling $200 in 2018.

Dmand AI lists 2 awards for Dr. Diaz, most recently CMS Stage 1 EHR in 2014.

Dr. Diaz graduated from University Of Michigan Medical School in 1998. Dr. Diaz is a member of ASCO.

Dr. Diaz is in network with 13 carriers, including Aetna, Excellus BlueCross BlueShield and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.